mRNA Vaccines and Therapeutics Market Size, Share, Report by 2033

June 17, 2024 Prathamesh

The global mRNA vaccines and therapeutics market size is expected to increase USD 18,936.64 million by 2033 from USD 1,241.64 mllion in 2023 with a CAGR of 31.32% between 2024 and 2033.

Key Points

North America dominated the mRNA vaccines and therapeutics market in 2023.
Asia Pacific is estimated to be the fastest growing during the forecast period of 2024-2033.
By disease type, the hereditary transthyretin-mediated amyloidosis genetic segment dominated the market in 2023.
By disease type, the acute hepatic porphyria segment is the fastest growing during the forecast period.
By route of administration type, the IV infusion segment dominated the market in 2023.
By route of administration type, the subcutaneous segment is the fastest growing during the forecast period.
By end-user type, the hospitals and clinics segment dominated the in 2023 and is also expected to be the fastest growing during the forecast period.

mRNA vaccines and therapeutics have emerged as revolutionary tools in modern medicine, offering new possibilities for preventing and treating various diseases. Messenger RNA (mRNA) technology has gained significant attention due to its role in the development of COVID-19 vaccines, marking a pivotal moment in vaccine history. This technology involves delivering synthetic mRNA into cells to instruct them to produce proteins that stimulate an immune response, thereby preventing infections or treating diseases like cancer. The mRNA vaccines and therapeutics market is poised for substantial growth, driven by increasing investments in research and development, expanding applications beyond infectious diseases, and advancements in delivery technologies.

Get a Sample: https://www.precedenceresearch.com/sample/4468

List of Contents

Growth Factors

Several factors contribute to the growth of the mRNA vaccines and therapeutics market. Firstly, the success of mRNA COVID-19 vaccines has demonstrated the efficacy and safety of this technology, boosting confidence among researchers, healthcare providers, and investors. Secondly, the potential to rapidly develop vaccines against emerging infectious diseases using mRNA platforms enhances their attractiveness. Thirdly, ongoing advancements in lipid nanoparticle delivery systems, which protect and deliver mRNA molecules into cells, have improved the efficiency and stability of mRNA therapeutics. Moreover, collaborations between pharmaceutical companies and research institutions to explore mRNA-based treatments for cancer, genetic disorders, and autoimmune diseases further drive market growth.

Trends in the mRNA Vaccines and Therapeutics Market

Several trends are shaping the mRNA vaccines and therapeutics market. One prominent trend is the development of personalized cancer vaccines using mRNA technology, targeting specific mutations in individual patients. Another trend is the exploration of mRNA as a platform for producing therapeutic proteins in situ within the body, potentially revolutionizing the treatment of genetic diseases and metabolic disorders. Additionally, the integration of mRNA technology with other therapeutic modalities, such as monoclonal antibodies and gene editing tools, represents a promising direction for future drug development efforts. Lastly, efforts to optimize mRNA stability, immunogenicity, and scalability are ongoing trends aimed at overcoming current challenges and expanding the applicability of mRNA therapeutics.

Region Insights

The mRNA vaccines and therapeutics market exhibit regional variations influenced by factors such as regulatory frameworks, healthcare infrastructure, and research capabilities. North America holds a leading position in the market, driven by strong investments in biotechnology, robust R&D activities, and supportive regulatory policies that facilitate rapid clinical trials and approvals. Europe follows closely, characterized by a strong biopharmaceutical industry and significant government funding for mRNA research and development. In Asia-Pacific, particularly in countries like China and Japan, increasing investments in healthcare infrastructure and rising prevalence of infectious diseases contribute to market growth. Emerging economies in Latin America and Africa are also witnessing a growing interest in mRNA technology, albeit at a slower pace, primarily driven by collaborations with international pharmaceutical companies and research institutions.

mRNA Vaccines and Therapeutics Market Scope

Report Coverage	Details
Market Size in 2023	USD 1,241.64 Million
Market Size in 2024	USD 1,630.52 Million
Market Size by 2033	USD 18,936.64 Million
Market Growth Rate from 2024 to 2033	CAGR of 31.32%
Largest Market	North America
Base Year	2023
Forecast Period	2024 to 2033
Segments Covered	Disease Type, Route of Administration, End-user Type, and Regions
Regions Covered	North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa

mRNA Vaccines and Therapeutics Market Dynamics

Drivers

Several key drivers propel the growth of the mRNA vaccines and therapeutics market. Firstly, the urgent need for effective vaccines against infectious diseases, highlighted by the COVID-19 pandemic, accelerates research and development efforts in mRNA technology. Secondly, the potential to address unmet medical needs in oncology, rare diseases, and chronic conditions through mRNA-based therapies attracts significant investments from biotechnology and pharmaceutical companies. Thirdly, advancements in manufacturing processes and scalability of mRNA production contribute to lowering production costs and improving accessibility of mRNA vaccines and therapeutics globally. Furthermore, partnerships and collaborations between academia, government agencies, and industry players foster innovation and expedite the translation of mRNA research into clinical applications.

Opportunities

The mRNA vaccines and therapeutics market presents several opportunities for growth and innovation. Firstly, expanding applications beyond infectious diseases to include oncology, cardiovascular diseases, and genetic disorders broadens the market potential and attracts diverse stakeholders. Secondly, leveraging mRNA technology for rapid response platforms against future pandemics and emerging infectious diseases enhances preparedness and global health security. Thirdly, expanding market access in low- and middle-income countries through technology transfer and capacity building initiatives promotes equitable distribution of mRNA vaccines and therapeutics. Additionally, advancements in mRNA delivery systems and formulation technologies open new avenues for developing next-generation mRNA-based therapies with enhanced efficacy and safety profiles.

Challenges

Despite promising growth prospects, the mRNA vaccines and therapeutics market faces several challenges. Firstly, ensuring long-term stability and immunogenicity of mRNA molecules remains a technical hurdle that requires ongoing research and development. Secondly, addressing public skepticism and misinformation surrounding mRNA technology, particularly in the context of vaccine hesitancy, poses communication and regulatory challenges. Thirdly, optimizing manufacturing processes to scale production while maintaining quality standards and cost-effectiveness presents operational challenges for industry stakeholders. Moreover, navigating complex regulatory pathways for approval and market authorization across different regions and countries requires strategic planning and compliance expertise.

mRNA Vaccines and Therapeutics Market Companies

Kernal Biologics Inc
Sanofi
Argos Therapeutics Inc
Charoen Pokphand Group
AIM Vaccine Corporation
CureVac SE
Ethris GmbH
Bohringer Ingelheim International GmbH
Arcturus
Daiichi Sankyo
GSK Plc.
Gennova Biopharmaceuticals Limited
Moderna, Inc.
BioNTech SE
Pfizer Inc.

Recent Developments

In May 2022, the first-in-Africa clinical trial of the mRNA HIV vaccine development program was launched by the non-profit scientific research organization, IAVI and a biotechnology company pioneering mRNA vaccines and therapeutics, Moderna, Inc. This is for immunogenicity, safety, and to strengthen regional scientific capacity.
In March 2024, the Dr, Jeffrey S. Weber and the team at NYU Langone Health’s Perlmutter Cancer Center and other cancer centers around the world, clinical trial tests personalized to the mRNA vaccine for the treatment of metastatic melanoma.
In April 2024, a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of diseases, VBI Vaccines Inc., announced that expanded collaboration with the Government of Canada to advance mRNA-launched enveloped virus-like particle (eVLP) vaccine platform.
In May 2024, a personalized mRNA cancer vaccine trial developed by Genentech and BioNTech for patients and launched by NHS.

Segments Covered in the Report

By Disease Type